Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium benzoate dose-finding trial in treatment refractory schizophrenia
ACTRN12621000327886Phase 2Completed
- Sponsor
- QIMR Berghofer Medical Research Institute
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sodium benzoate in schizophrenia (4 arms), sponsored by QIMR Berghofer Medical Research Institute. Primary endpoint: PANSS total score at week 6. Started Dec 2021; status: completed.
02
Drugs
sodium benzoate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ACTRN12621000327886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000327886.